Literature DB >> 8729945

Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro.

H Depenbrock1, A Shirvani, J Rastetter, A R Hanauske.   

Abstract

Epidermal Growth Factor (EGF) is a mitogenic peptide that binds to surface membrane receptors (EGFR) of breast cancer cells. After binding, secondary transmitter molecules are activated by tyrosine phosphorylation of the intracellular receptor domaine. The activity of the EGF/EGFR system can be modulated by a variety of chemically unrelated compounds including cytostatic agents. The purpose of our present study was to determine the effects of vinorelbine, a novel semisynthetic vinca alkaloid on EGF receptor binding on human breast cancer cells. We have found that MDA-231 and MDA-468 cells bind substantially more [125I]-EGF after preincubation with vinorelbine. This effect was concentration- and time-dependent reaching a maximum at 100 ng/ml and 24 h incubation. Subsequent experiments showed an increase in the rate of EGF binding as well as maximal binding capacity. Scatchard analysis of binding experiments under equilibrium conditions indicated that this was mainly due to an increase in the number of apparent EGF binding sites. Modulation of EGF receptor binding by vinorelbine was not detectable when isolated membranes were used indicating that intact cytoplasmatic mechanisms are required for the upregulation of EGF receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8729945     DOI: 10.1007/BF00873799

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  17 in total

1.  Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma.

Authors:  E R Sargent; L G Gomella; A Belldegrun; W M Linehan; A Kasid
Journal:  J Urol       Date:  1989-11       Impact factor: 7.450

2.  Modulation of epidermal growth factor receptors by human alpha interferon.

Authors:  K C Zoon; Y Karasaki; D L zur Nedden; R Q Hu; H Arnheiter
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

3.  Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells.

Authors:  M B Meyers; W P Shen; B A Spengler; V Ciccarone; J P O'Brien; D B Donner; M E Furth; J L Biedler
Journal:  J Cell Biochem       Date:  1988-10       Impact factor: 4.429

4.  Receptor binding and processing of epidermal growth factor by human breast cancer cells.

Authors:  C K Osborene; B Hamilton; M Nover
Journal:  J Clin Endocrinol Metab       Date:  1982-07       Impact factor: 5.958

5.  Effect of vinblastine on the insulin-receptor interaction in mammalian heart muscle.

Authors:  J Eckel; H Reinauer
Journal:  Biochem Biophys Res Commun       Date:  1980-02-27       Impact factor: 3.575

6.  Epidermal growth factor receptors in human breast cancer.

Authors:  R Pérez; M Pascual; A Macías; A Lage
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

7.  Relationship between biological responsiveness to phorbol esters and receptor levels in GH4C1 rat pituitary cells.

Authors:  S Jaken; A H Tashjian; P M Blumberg
Journal:  Cancer Res       Date:  1981-12       Impact factor: 12.701

8.  Adriamycin causes up regulation of epidermal growth factor receptors in actively growing cells.

Authors:  G Zuckier; T R Tritton
Journal:  Exp Cell Res       Date:  1983-10       Impact factor: 3.905

9.  Early events elicited by bombesin and structurally related peptides in quiescent Swiss 3T3 cells. I. Activation of protein kinase C and inhibition of epidermal growth factor binding.

Authors:  I Zachary; J W Sinnett-Smith; E Rozengurt
Journal:  J Cell Biol       Date:  1986-06       Impact factor: 10.539

10.  Long-term, heterologous down-regulation of the epidermal growth factor receptor in PC12 cells by nerve growth factor.

Authors:  P Lazarovici; G Dickens; H Kuzuya; G Guroff
Journal:  J Cell Biol       Date:  1987-06       Impact factor: 10.539

View more
  5 in total

1.  Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines.

Authors:  Kaisa Erjala; Misa Raitanen; Jarmo Kulmala; Reidar Grénman
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-05       Impact factor: 4.553

2.  A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.

Authors:  Hanna K Sanoff; Janine M Davies; Christine Walko; William Irvin; Larry Buie; Kimberly Keller; Anastasia Ivanova; Wing-Keung Chiu; Bert H O'Neil; Thomas E Stinchcombe; E Claire Dees
Journal:  Invest New Drugs       Date:  2010-04-13       Impact factor: 3.850

3.  Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood.

Authors:  Maura Massimino; Veronica Biassoni; Rosalba Miceli; Elisabetta Schiavello; Monika Warmuth-Metz; Piergiorgio Modena; Michela Casanova; Emilia Pecori; Felice Giangaspero; Manila Antonelli; Francesca Romana Buttarelli; Paolo Potepan; Bianca Pollo; Raffaele Nunziata; Filippo Spreafico; Marta Podda; Andrea Anichini; Carlo Alfredo Clerici; Iacopo Sardi; Loris De Cecco; Udo Bode; Ferdinand Bach; Lorenza Gandola
Journal:  J Neurooncol       Date:  2014-04-03       Impact factor: 4.130

4.  Two-layer modular analysis of gene and protein networks in breast cancer.

Authors:  Alok Srivastava; Suraj Kumar; Ramakrishna Ramaswamy
Journal:  BMC Syst Biol       Date:  2014-07-05

5.  VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma.

Authors:  Sutapa Sinha; Ying Cao; Shamit Dutta; Enfeng Wang; Debabrata Mukhopadhyay
Journal:  J Cell Mol Med       Date:  2008-11-07       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.